<br>        Inclusion Criteria:<br><br>          -  Informed consent obtained before any trial-related activities. (Trial-related<br>             activities are any procedure that would not have been performed during normal<br>             management of the subject.)<br><br>          -  Ongoing participation in the pathfinder™2 (NN7088-3859) or the pathfinderTM 4<br>             (NN7088-3861) trial and having received greater than or equal to 5 doses of N8-GP<br><br>          -  Undergoing major surgery requiring daily monitoring of FVIII:C (FVIII activity) and<br>             wound status for at least 3 days<br><br>          -  The patient and/or Legally Acceptable Representative (LAR) is capable of assessing a<br>             bleeding episode, keeping an eDiary, capable of home treatment of bleeding episodes<br>             and otherwise capable of following the trial procedures<br><br>        Exclusion Criteria:<br><br>          -  Known or suspected hypersensitivity to trial product including allergy to hamster<br>             protein or related products<br><br>          -  Previous withdrawal from the pathfinder™2 (NN7088-3859) or the pathfinderTM 4<br>             (NN7088-3861) trial after administration of trial product, except interruption due to<br>             inclusion in this pathfinderTM 3 trial (NN7088-3860)<br><br>          -  The receipt of any investigational medicinal product (except N8-GP) within 30 days<br>             prior to enrolment into the trial. (For Brazil, only: Participation in a previous<br>             clinical trial within one year prior to screening for this trial (Visit 1), unless<br>             there is a direct benefit to the research subject, at the Investigator's discretion)<br><br>          -  FVIII inhibitors at least 0.6 BU (Bethesda Units)/mL at screening<br><br>          -  Previous arterial thrombotic events (e.g. myocardial infarction and intracranial<br>             thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by<br>             available medical records)<br><br>          -  Immune modulating or chemotherapeutic medication<br><br>          -  Any disease (liver, kidney, inflammatory and mental disorders included) or condition<br>             which, according to the Investigator's judgement, could imply a potential hazard to<br>             the patient, interfere with trial participation or trial outcome<br><br>          -  Unwillingness, language or other barriers precluding adequate understanding and/or<br>             cooperation<br>